Opthea (NASDAQ:OPT) Lowered to Market Perform Rating by Oppenheimer

Oppenheimer downgraded shares of Opthea (NASDAQ:OPT) from an outperform rating to a market perform rating in a research report report published on Monday morning, MarketBeat.com reports.

OPT has been the subject of a number of other research reports. Canaccord Genuity Group raised Opthea to a “strong-buy” rating in a research report on Tuesday, December 17th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Opthea in a research note on Friday, February 28th.

Opthea Trading Up 7.2 %

NASDAQ:OPT opened at $3.41 on Monday. The company has a fifty day moving average of $4.43 and a 200 day moving average of $4.07. Opthea has a 52 week low of $1.79 and a 52 week high of $6.30.

Institutional Trading of Opthea

Several large investors have recently bought and sold shares of OPT. Hsbc Holdings PLC purchased a new position in shares of Opthea in the 4th quarter valued at approximately $556,000. Jane Street Group LLC purchased a new position in Opthea during the third quarter valued at $114,000. Citadel Advisors LLC bought a new stake in shares of Opthea during the 4th quarter valued at $79,000. Twin Lakes Capital Management LLC purchased a new stake in shares of Opthea in the 3rd quarter worth about $81,000. Finally, OLD Mission Capital LLC bought a new position in shares of Opthea in the 4th quarter worth about $42,000. 55.95% of the stock is owned by institutional investors.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.